Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.

Expert opinion on drug safety - 1 Nov 2017

Talamo Guevara Maria, McColley Susanna A

Abstract excerpt

INTRODUCTION: Lumacaftor-ivacaftor is indicated for treatment of cystic fibrosis (CF) in patients homozygous for the Phe-508del cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations. In clinical trials, treated patients showed improved pulmonary function, reduced pulmonary exacerbations, and other benefits. This article reviews safety of this therapy. Areas covered: Safety findings in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to Cytochrome P-450 CYP3A

Share to Drug Combinations

Share to Drug Interactions

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 28846049
DOI: 10.1080/14740338.2017.1372419
PMCID: PMC6209511

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.PMID 28846049Read ↗

A safety evaluation of ivacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.Semantic proximity Read ↗

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.Semantic proximity Read ↗

Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.Semantic proximity Read ↗

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.Semantic proximity Read ↗

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.Semantic proximity Read ↗

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.Semantic proximity Read ↗

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Semantic proximity Read ↗

Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Semantic proximity Read ↗

A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read ↗

Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.Semantic proximity Read ↗

Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.